
Samsung Tops $750 Billion Market Cap, Bets on AI to Reclaim Tech Leadership
Samsung Electronics has surpassed a $750 billion market capitalization, becoming the first South Korean company to reach the
Curated content that matters
Explore stories across diverse categories

Samsung Electronics has surpassed a $750 billion market capitalization, becoming the first South Korean company to reach the

Paris Baguette, a South Korea–based bakery café chain operated by SPC Group that sells breads, pastries and coffee

Hyundai Motor is pressing ahead with its Middle East expansion, strengthening strategic ties with Public Investment Fund as

South Korean cryptocurrency exchange Bithumb is facing escalating regulatory pressure after receiving a record fine and partial business
Photo=Motionelements K-pop group BTS will stage a free live concert on 3/21 at 8:00 p.m. local time to mark the release of its fifth full-length album, ARIRANG, with ticket reservations opening later this month. According to an announcement posted on the fan platform Weverse at 12:00 a.m. on 2/9, ticketing for the event, titled “BTS The Comeback Live | ARIRANG,”
Photo=Motionelements Samsung Electronics ranked first among global companies in the number of U.S. patents granted last year, marking its fourth consecutive year at the top, according to a report released 2/8 by patent analytics firm IFI Claims. A total of 323,272 patents were registered in the United States in 2025, the report showed. Samsung Electronics secured 7,054 patents, accounting for
The cost of preparing a traditional Lunar New Year ceremonial table in South Korea rose by more than 4% from a year earlier, underscoring how food inflation remains embedded in household budgets during one of the country’s most important holidays. In South Korea, Seollal, as the Lunar New Year is known, is a multiday family gathering centered on ancestral rites
(Photo=Hotel Shilla) The global travel-retail industry is still recalibrating after the pandemic, with airport and inflight duty-free operators facing thinner margins, volatile passenger flows and rising financing costs. As those pressures persist, companies are increasingly reassessing whether overseas investments built for a pre-2020 growth cycle still justify the capital they tie up. Against that backdrop, Hotel Shilla, a South Korean
(Photo=Celltrion) In the U.S. healthcare system, access matters more than approval. A drug can clear regulators and still fail commercially if it cannot pass through the tightly controlled formularies run by pharmacy benefit managers. This month, one South Korean pharmaceutical company crossed that threshold in one of the most closely guarded corners of the American drug market. Celltrion has secured